Clinical Trial Update: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. [Phase 2]

View source ↗

Summary

A Phase 2 rollover study from Novartis continues Sabatolimab (MBG453) treatment for patients who completed a prior study, to assess continued benefit in myelody…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Sabatolimab (MBG453) (sabatolimab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 2 | Status: ACTIVE_NOT_RECRUITING